HIV reservoirs in the brain: Where, when, how, and what do they mean for our patients?

Size: px
Start display at page:

Download "HIV reservoirs in the brain: Where, when, how, and what do they mean for our patients?"

Transcription

1 HIV Reservoirs in the Brain: Where, When, How, and What Do They Mean for Our Patients? Serena S. Spudich, MD, MA Professor of Neurology Yale University New Haven, Connecticut FORMATTED: // HIV reservoirs in the brain: Where, when, how, and what do they mean for our patients? Slide of IAS USA New York, NY November, Serena S. Spudich, MD Department of Neurology Yale University Berlin patient revealed possibility of HIV cure, creating new critical question is the brain an HIV reservoir? Slide of Doing well off ART > 8 years No replication competent HIV Waning HIV antibodies No HIV specific T cells Slide courtesy of Steve Deeks

2 Key questions relevant to brain reservoirs for HIV Slide of Do HIV reservoirs exist in the brain during cart? How should we consider the brain in our management of patients? How/when are HIV reservoirs established in the brain? How will HIV cure strategies impact the brain? Thuso: year old man with difficulty walking Slide of yo man presented / with leg weakness and balance difficulty, vague cognitive symptoms, + urinary incontinence. Diagnosed with HIV in 8, cart naïve. Labs: Plasma HIV RNA. million cps/ml and CD cells/ul. CSF microbiology all negative, except CSF HIV RNA > million cps/ml. MRI Brain (FLAIR sequence) shown below with atrophy and diffuse subcortical white matter changes. Slide 8 of Thuso: year old man with difficulty walking HIV RNA(lo Diagnosis: HIV associated dementia. QNZP Since the beginning of the epidemic, CNS involvement has been a hallmark of HIV. In some individuals, HIV particularly manifests as CNS dysfunction with profound CNS HIV replication. Days post ART initiation Digit Symbol (DSY) -8 - QNPZ summarized neurologic DSY performance How does this CNS impact change with potent ART? Do reservoirs for HIV exist within the brain in most patients? Days

3 Mechanisms of CNS HIV infection prior to ART Brain Neurotoxic products (free radicals, cytokines) Slide 9 of HIV proteins (gp, tat) Neopterin Chemokines (IP, MCP ) Blood brain barrier breakdown Blood HIV tat Key questions relevant to brain reservoirs for HIV Slide of Do HIV reservoirs exist in the brain during cart? How should we consider the brain in our management of patients? How/when are HIV reservoirs established in the brain? How will HIV cure strategies impact the brain? Persistent macrophage/microglial activation on cart with plasma viral suppression / HIV Slide of Positron emission tomography (PET): Abnormal brain uptake of ligand specific for activated microglial cells (> years of ART vs HIV ). Brain autopsy: Increased activated microglia (CD8+ cells) in (>. years ART vs HIV ). CSF: Elevated CSF neopterin, marker of macrophage activation, associates with detectable CSF HIV RNA by single copy assay (> years of ART). Garvey et al, AIDS. ; Anthony et al, J Neuropath Exp Neur, ; Dahl et al, AIDS.

4 HIV DNA detected in brain on ART with plasma viral suppression (sudden death) Slide of HIV RNA seldom measurable in brain Slide and data courtesy of Joe Wong Wong, Yukl, et al, Keystone HIV Persistence Conference, April HIV DNA detected in brain on ART with plasma viral suppression Sample type Sequence # Unique Patient ID # +ve PCR reactions /cell # determined sequences GPDH V T8 / / N - / / N - / / N - / / N - > / / Y Slabs / / Y T8 PBMC - - Slide of CTRPNNNTRK S I H I - - GPGR AFYTTGE I I G D I RQAHC N L R. R. QR V. I. K. -. NM D S R R R R D R R R E D I P R E D.. S S. FA.. DV D S.. A.. DV I R Q T.. A.. D. V Y SC. A.. VV P. R Slide and data courtesy of Melissa Churchill Churchill, et al, Keystone HIV Persistence Conference, April Persistent CNS HIV replication on ART with plasma viral suppression: CNS escape Slide of Lamivudine Abacavir Lopinavir/r hand tremor, ataxia, slurred speech, aphasia Latest CD 8 cells/ul; nadir CD cells/ul Peluso et al., AIDS,.

5 Persistent CNS HIV replication on ART with plasma viral suppression: CNS escape Slide of CSF HIV RNA CSF WBC = cells/ul Peluso et al., AIDS,. Persistent CNS HIV replication on ART with plasma viral suppression: CNS escape PI: IV, KR, MI, IV, LP, V8A RT: ML, ED, DN, V8I, M8V, LW, TY Abacavir Lamivudine Darunavir/r Nevirapine Zidovudine Resolution of signs and symptoms Zidovudine Didanosine Lamivudine Stavudine Abacavir Tenofovir Nevirapine Delavirdine Efavirenz Saquinavir Indinavir Ritonavir Nelfinavir Amprenavir Lopinavir/r Atazanavir Possible Possible Slide of No Evidence of No Evidence of No Evidence of Possible Possible Peluso et al., AIDS,. Log Log HIV HIV viral viral load load (RNA (RNA copies/ cp/ml) THINC Subject : CSF escape at two time intervals Pre- HAART T T Blood plasma St ar t ed DRV/ r/ TDF/ FTC years after diagnosis CSF Months on HAART Slide of Persistent CNS HIV replication on ART with plasma viral suppression: CNS escape Perc ent Infectivity at Low CD Elevated macrophage tropism of CSF escape population Ba L JRCSF D E9 F A UNC Joseph et al., THINC study

6 Jake: Young man with recent infection, hesitant to start ART 9 yo man diagnosed in May,, probable acute HIV syndrome in Oct. On no meds, works as an electrical engineer; lives alone and has good support network. He wants to avoid treatment as long as possible. / / 9/ CD count 8 CD % HIV RNA 9 Slide 8 of Key questions relevant to brain reservoirs for HIV Slide 9 of Do HIV reservoirs exist in the brain during cart? How should we consider the brain in our management of patients? How/when are HIV reservoirs established in the brain? Early HIV infection studies How will HIV cure strategies impact the brain? HIV traffics into the CNS in early infection Slide of 8 HIV RNA Levels Plasma log copies/ml 9 8 Days Post HIV Transmission

7 HIV traffics into the CNS in early infection Slide of 8 HIV RNA Levels Plasma CSF log copies/ml 9 8 Days Post HIV Transmission HIV traffics into the CNS in early infection Slide of 8 HIV RNA Levels CSF log copies/ml 9 8 Days Post HIV Transmission CSF Neopterin Slide of Macrophage activation in the CNS is triggered in early infection 8 nmol/l 9 8 Days Post HIV Transmission Neopterin, biomarker of macrophage activation, is elevated in the CNS compared to HIV negative (dotted line) throughout early infection.

8 Neuronal injury begins during early infection Slide of CSF NFL ng/l HIV- AHI PHI CHI Neurofilament Light Chain (NFL) specific CSF biomarker of axonal injury Peluso et al., JID Slide of 8 HIV RNA Levels CSF log copies/ml 9 8 Days Post HIV Transmission Variable compartmentalization of env sequences between plasma and CSF in primary infection Slide of A % % % % % % 8% % % - months (n=) - months (n=) Blood CSF Not Analyzed Equilibrated (-) Equilibrated (+) Intermediate Compartmentalized Sturdevant C., PloS Pathogens 8

9 Slide of Key questions relevant to brain reservoirs for HIV Slide 8 of Do HIV reservoirs exist in the brain during cart? How should we consider the brain in our management of patients? How/when are HIV reservoirs established in the brain? How will HIV cure strategies impact the brain? CSF HIV and CNS inflammation after ART interruption HIV RNA (log cps/ml) Plasma HIV RNA Slide 9 of 8 HIV RNA (log cps/ml) CSF HIV RNA 8 CSF WBCs cells/ L Price, Deeks, J Neurovirology. 8 Days 9

10 How will HIV cure strategies affect the CNS? ART cure intervention ART Interruption ART Slide of Pre ART On ART During intervention/ before ATI At plasma rebound (or before) On ART in follow up protocol CSF: inflammatory markers, virology, injury markers Neuroimaging: MRS, volumetrics, DTI & rs fmri at Tesla magnet strength Clinical: Neurological exams & neuropsychological assessments Collaborators: V. Valcour, J. Ananworanich Slide of SEARCH : HIV cure intervention with HDAC inhibitor, followed by treatment interruption Wk LP/MRI/NP Start VHM Wk Detectable plasma HIV LP/NP RNA Stop VHM, LP/NP Begin ART interrup9on Resume ART F/u on ART MRI/NP Kroon, et al., IAS Cure Symposium & IAS, SEARCH : HIV cure intervention with HDAC inhibitor, followed by treatment interruption A. Plasma HIV RNA B. CSF HIV RNA Standard Assay Slide of HIV RNA (cps/ml) HIV RNA (cps/ml) Baseline Wk VHM ATI On ART Baseline Wk VHM ATI C. CSF HIV RNA Single Copy Assay VHM: Vorinostat (HDAC inhibitor) + Hydroxychloroquine + Maraviroc HIV RNA (cps/ml) Baseline Wk VHM ATI Kroon, et al., IAS Cure Symposium & IAS,

11 SEARCH : HIV cure intervention with HDAC inhibitor, followed by treatment interruption Protein (mg/dl) A. CSF Protein IP-/CXCL (pg/ml) B. CSF IP-/CXCL p =. Slide of Baseline Wk VHM ATI Baseline Wk VHM ATI C. CSF MCP-/CCL- D. CSF Neopterin MCP-/CCL- (pg/ml) Baseline Wk VHM ATI VHM: Vorinostat (HDAC inibitor) + Hydroxychloroquine + Maraviroc CSF Neopterin (nmol/l) Baseline Wk VHM ATI Kroon, et al., IAS Cure Symposium & IAS, Key questions relevant to brain reservoirs for HIV Slide of Do HIV reservoirs exist in the brain during cart? How should we consider the brain in our management of patients? How/when are HIV reservoirs established in the brain? How will HIV cure strategies impact the brain? ACTG A: Effects of ART intensification on the brain Slide of Randomized, placebo controlled, double blinded phase IV clinical trial, 9 weeks Study Population (n=8; arms=) Mild neurocognitive impairment (includes neuroasymptomatic) On stable ART treatment > year Plasma HIV RNA less than copies/ml Study Regimens A: No intensification B: Intensification with DTG C: Intensification with DTG and MVC Weill Cornell Uptown Site E 8 th St at York Avenue Valery Hughes, FNP 9 Weill Cornell Chelsea Site W rd St between th and th Todd Stroberg, RN 98

12 Slide of Clinical management of HIV and the brain in USA HIV treatment guidelines ( Treat all individuals at the time of HIV diagnosis. HIV guidelines now incorporate CNS considerations: Due to CNS toxicities, efavirenz no longer in first line recommended regimens. Treatment recommendations for HIV Associated Dementia (no efavirenz, favor regimens with higher presumed CNS penetration). Evaluation/treatment of symptomatic CNS escape including lumbar puncture for CSF viral load, CSF drug resistance testing and consideration of CNS penetration. Acknowledgements Yale: Michael Kozal Brinda Emu Leah Le Jen Chiarella Barbara Turcotte Laurie Andrews Sebastian Urday Michael Peluso Andrew Young Joome Suh Idil Kore Elham Rahimy Andrew Silverman Tess O Meara UCSF/San Francisco: Victor Valcour Joanna Hellmuth Collin Adams Lauren Wendelken Richard W. Price Evelyn Lee Julia Peterson Rick Hecht Chris Pilcher UCSF Options Study Magnet Staff Teri Liegler Study Participants UNC: Ron Swanstrom Sarah Joseph Christa Sturdevant Gretja Schnell Kevin Robertson Joe Eron THINC team Sydney: Bruce Brew Sarah Palmer Innsbruck: Dietmar Fuchs WRAIR/MHRP Jintanat Ananworanich Sodsai Tovanabutra Gustavo Kijak Suteeraporn Pinyakorn Nelson Michael Jerome Kim Merlin Robb U. Gothenburg: Lars Hagberg Magnus Gisslen Funding Support Henrik Zetterberg Milan: Paola Cinque NIH RMH RMH9999 RMH8 RMH9 R NS89 KMH W8XWH ; IAA number NIAID Y AI US Military HIV Research Program Slide of Study Participants Thai Red Cross AIDS Res Center/SEARCH Nittaya Phanuphak Praphan Phanuphak Mark de Souza Frits van Griensven James Fletcher Eugene Kroon Donn Colby Carlo Nitiya Chomchey Duanghathai Suttichom Somprartthana Rattanamanee Peeraya Mungu Putthachard Saengtawan Tippawan Pankam

Serena S. Spudich, MD Professor of Neurology Yale University New Haven, Connecticut

Serena S. Spudich, MD Professor of Neurology Yale University New Haven, Connecticut HIV Reservoirs in the Brain: Where, When, How, and What Do They Mean for Our Patients? Serena S. Spudich, MD Professor of Neurology Yale University New Haven, Connecticut FORMATTED: // Financial Relationships

More information

HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV

HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV Shibani S. Mukerji MD, PhD Massachusetts General Hospital, Division of Immunologic, Inflammatory and Infectious Neurological Diseases Dana-Farber

More information

IAS 2016 Towards an HIV Cure Symposium Durban, South Africa.

IAS 2016 Towards an HIV Cure Symposium Durban, South Africa. Effect of vorinostat, hydroxychloroquine and maraviroc combination therapy on viremia following treatment interruption in individuals treated during acute HIV infection Eugène Kroon, Jintanat Ananworanich,

More information

AIDS 2011, 3, 2011 RW

AIDS 2011, 3, 2011 RW Treating CNS HIV Infection and Disease Why, How and When? Richard W. Price, M.D. Department of Neurology, UCSF/SFGH Preface: Reasons for Renewed Interest in Treatment of CNS HIV Continued CNS infection/disease

More information

Central Nervous System Penetration of ARVs: Does it Matter?

Central Nervous System Penetration of ARVs: Does it Matter? NORTHWEST AIDS EDUCATION AND TRAINING CENTER Central Nervous System Penetration of ARVs: Does it Matter? Christina M. Marra, MD Neurology and Medicine (Infectious Diseases) University of Washington 15

More information

Clinical notes: Management of HAART in patients with HAND

Clinical notes: Management of HAART in patients with HAND Clinical notes: Management of HAART in patients with HAND Paola Cinque Dipartment of Infectious Diseases San Raffaele Scientific Institute, Milano, Italy 11 Residential Course on Clinical Pharmacology

More information

Acute HIV Infection. Acute

Acute HIV Infection. Acute Acute HIV In nfection n Acute HIV Infection Jintanat t Ananworanich, MD, PhD Investigator, AFRIMS (Armed Forces Research Institute of Medical Sciences) Chief of SEARCH Deputy Director in Scientific Affairs,

More information

HIV associated CNS disease in the era of HAART

HIV associated CNS disease in the era of HAART HIV associated CNS disease in the era of HAART CSF/CNS penetration and efficacy Acknowledgements Peter Portegies Department of Neurology, AMC Mark van der Valk Department of Internal Medicine/Infectious

More information

State of the ART: HIV Cure where are we now and. where are we going? Jintanat Ananworanich, MD, PhD MHRP

State of the ART: HIV Cure where are we now and. where are we going? Jintanat Ananworanich, MD, PhD MHRP State of the ART: HIV Cure where are we now and ì where are we going? Jintanat Ananworanich, MD, PhD Associate Director for Therapeu1cs Research US Military HIV Research Program (MHRP) Maryland, USA Deputy

More information

Management of NRTI Resistance

Management of NRTI Resistance NORTHWEST AIDS EDUCATION AND TRAINING CENTER Management of NRTI Resistance David Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington

More information

MHRP. Outline. Is HIV cure possible? HIV persistence. Cure Strategies. Ethical and social considerations. Short video on patients perspectives on cure

MHRP. Outline. Is HIV cure possible? HIV persistence. Cure Strategies. Ethical and social considerations. Short video on patients perspectives on cure Outline Is HIV cure possible? Ø HIV persistence Cure Strategies Ethical and social considerations Short video on patients perspectives on cure A Case of Cure Off ART Treatment Mechanism Lesson The Berlin

More information

HIV Neurology Persistence of Cognitive Impairment Despite cart

HIV Neurology Persistence of Cognitive Impairment Despite cart HIV Neurology Persistence of Cognitive Impairment Despite cart Victor Valcour MD PhD Professor of Medicine Memory and Aging Center, Dept. of Neurology University of California San Francisco, USA 8 th International

More information

Somnuek Sungkanuparph, M.D.

Somnuek Sungkanuparph, M.D. HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor

More information

2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012

2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change

More information

MHRP Studies in Early Treatment and The Journey towards HIV Remission

MHRP Studies in Early Treatment and The Journey towards HIV Remission MHRP Studies in Early Treatment and The Journey towards HIV Remission Merlin L. Robb, MD Deputy Director of MHRP for Clinical Research Director, HJF Component of MHRP US Military HIV Research Program mrobb@hivresearch.org

More information

HIV DISEASE! Neurobehavioral! Neuromedical. Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego

HIV DISEASE! Neurobehavioral! Neuromedical. Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego HIV DISEASE! Neuromedical Neurobehavioral! HIV Neurobehavioral Disturbances HIV Associated Neurocognitive

More information

HIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD. Professor of Medicine University of California, San Diego

HIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD. Professor of Medicine University of California, San Diego HIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD Professor of Medicine University of California, San Diego Disclosures Grant/research support Abbvie Gilead Sciences

More information

Second-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER

Second-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation

More information

International Symposium on. Barcelona, May 5 th and 6 th 2011

International Symposium on. Barcelona, May 5 th and 6 th 2011 th International Symposium on Barcelona, May 5 th and 6 th 2011 Pathogenesis of Neurocognitive Impairment in HIV-infected persons Paola Cinque Dipartimento di Malattie Infettive Istituto Scientifico San

More information

ART and Prevention: What do we know?

ART and Prevention: What do we know? ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:

More information

Compartmentalized HIV and SIV Populations in the Central Nervous System Are Associated with Neuropathogenesis

Compartmentalized HIV and SIV Populations in the Central Nervous System Are Associated with Neuropathogenesis Compartmentalized HIV and SIV Populations in the Central Nervous System Are Associated with Neuropathogenesis Gretja Schnell Graduate Student Laboratory of Ronald Swanstrom Department of Microbiology and

More information

Pediatric Antiretroviral Resistance Challenges

Pediatric Antiretroviral Resistance Challenges Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden

More information

Distribution and Effectiveness of Antiretrovirals in the Central Nervous System

Distribution and Effectiveness of Antiretrovirals in the Central Nervous System Distribution and Effectiveness of Antiretrovirals in the Central Nervous System Scott Letendre, MD Associate Professor of Medicine HIV Neurobehavioral Research Center and Antiviral Research Center University

More information

Dr Alan Winston. Imperial College Healthcare NHS Trust London. 7-8 October 2010, Queen Elizabeth II Conference Centre, London.

Dr Alan Winston. Imperial College Healthcare NHS Trust London. 7-8 October 2010, Queen Elizabeth II Conference Centre, London. BHIVA AUTUMN CONFERENCE 2010 Including CHIVA Parallel Sessions Dr Alan Winston Imperial College Healthcare NHS Trust London 7-8 October 2010, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE

More information

Cure: Early Detection and Early Treatment"

Cure: Early Detection and Early Treatment Cure: Early Detection and Early Treatment" ECHO (RV217) and RV 254 Merlin L. Robb, MD, Dr. Jintanat Ananworanich, and Dr. Jerome Kim and Dr. Nelson Michael 4 th International Workshop on HIV & Women 13-14

More information

Review Neurologic Complications of HIV Infection

Review Neurologic Complications of HIV Infection Review Neurologic Complications of HIV Infection Serena S. Spudich, MD; Beau M. Ances, MD, PhD More than 30 years into the HIV epidemic, research efforts are focusing on better understanding how the central

More information

Immunologic Failure and Chronic Inflammation. Steven G. Deeks Professor of Medicine University of California, San Francisco

Immunologic Failure and Chronic Inflammation. Steven G. Deeks Professor of Medicine University of California, San Francisco Immunologic Failure and Chronic Inflammation Steven G. Deeks Professor of Medicine University of California, San Francisco Plasma HIV RNA (log) 6 5 4 3 2 52 year old HIV+/HCV+ man presents with symptomatic

More information

With over 20 drugs and several viable regimens, the mo6vated pa6ent with life- long access to therapy can control HIV indefinitely, elimina6ng the

With over 20 drugs and several viable regimens, the mo6vated pa6ent with life- long access to therapy can control HIV indefinitely, elimina6ng the Towards an HIV Cure Steven G. Deeks, MD Professor of Medicine in Residence HIV/AIDS Division University of California, San Francisco (UCSF) WorldMedSchool; July 22, 2013 1 With over 20 drugs and several

More information

Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches

Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor

More information

Title: Distinct Biomarker Signatures in HIV Acute Infection Associate with. Viral Dynamics and Reservoir Size. Supplemental Material

Title: Distinct Biomarker Signatures in HIV Acute Infection Associate with. Viral Dynamics and Reservoir Size. Supplemental Material 1 2 Title: Distinct Biomarker Signatures in HIV Acute Infection Associate with Viral Dynamics and Reservoir Size 3 Supplemental Material 1 11 12 13 1 1 1 1 1 1 2 21 22 23 2 Authors: Jeffrey E. Teigler

More information

Management of patients with antiretroviral treatment failure: guidelines comparison

Management of patients with antiretroviral treatment failure: guidelines comparison The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral

More information

Clinical skills building - HIV drug resistance

Clinical skills building - HIV drug resistance Clinical skills building - HIV drug resistance Richard Lessells Clinical case 44-year old HIV-positive male HIV diagnosis 2010 Pre-treatment CD4+ count not known Initiated first-line ART (TDF/FTC/EFV)

More information

MDR HIV and Total Therapeutic Failure. Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007

MDR HIV and Total Therapeutic Failure. Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007 MDR HIV and Total Therapeutic Failure Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007 Objectives Case study Definitions Fitness Pathogenesis of resistant virus

More information

Supplementary Figure 1. Gating strategy and quantification of integrated HIV DNA in sorted CD4 + T-cell subsets.

Supplementary Figure 1. Gating strategy and quantification of integrated HIV DNA in sorted CD4 + T-cell subsets. Supplementary information HIV reservoir size and persistence are driven by T-cell survival and homeostatic proliferation. Chomont, N., M. El Far, P. Ancuta, L. Trautmann, F. A. Procopio, B. Yassine-Diab,

More information

Resistance Workshop. 3rd European HIV Drug

Resistance Workshop. 3rd European HIV Drug 3rd European HIV Drug Resistance Workshop March 30-April 1 st, 2005 Christine Hughes, PharmD Clinical Associate Professor Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Tenofovir resistance

More information

Update on Neurologic Complications in Persons With HIV Infection: 2017

Update on Neurologic Complications in Persons With HIV Infection: 2017 Update on Neurologic Complications in Persons With HIV Infection: 2017 FORMATTED: MM/DD/YY Chicago, Illinois: May 10, 2017 Dennis Kolson, MD, PhD Professor of Neurology University of Pennsylvania Philadelphia,

More information

Continuing Education for Pharmacy Technicians

Continuing Education for Pharmacy Technicians Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected

More information

Didactic Series. Archive Genotype Resistance Testing in the Setting of Regimen Switching

Didactic Series. Archive Genotype Resistance Testing in the Setting of Regimen Switching Didactic Series Archive Genotype Resistance Testing in the Setting of Regimen Switching Craig Ballard, Pharm.D., AAHIVP UCSD Medical Center Owen Clinic June 11, 2015 ACCREDITATION STATEMENT: University

More information

Criteria for Oral PrEP

Criteria for Oral PrEP Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates

More information

THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work

THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core

More information

Comprehensive Guideline Summary

Comprehensive Guideline Summary Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and

More information

How to best manage HIV patient?

How to best manage HIV patient? How to best manage HIV patient? 1 2 Treatment Treatment Failure success HIV therapy = a long life therapy Why do we want to change a suppressive ART? Side effect Comorbidities Reduce drug burden How to

More information

Disclosures 12/7/17. UPDATES IN HIV NEUROLOGY Felicia Chow, MD, MAS University of California, San Francisco December 7, 2017

Disclosures 12/7/17. UPDATES IN HIV NEUROLOGY Felicia Chow, MD, MAS University of California, San Francisco December 7, 2017 UPDATES IN HIV NEUROLOGY Felicia Chow, MD, MAS University of California, San Francisco December 7, 2017 Disclosures I have nothing to disclose. Brain Compartment Zayyad et al. Curr HIV/AIDS Rep 2015 Clinical

More information

Overview. HIV Brain Injury. HIV characteristics. HIV Dementia 11/6/2010

Overview. HIV Brain Injury. HIV characteristics. HIV Dementia 11/6/2010 Overview HIV Brain Injury Victor Valcour MD Associate Professor Division of Geriatric Medicine and Department of Neurology/UCSF The neuropathology of HIV HIV Dementia a current snapshot Scenarios of rapid

More information

HIV in in Women Women

HIV in in Women Women HIV in Women Susan L. Koletar, MD The Ohio State University How Many of These Women Have HIV? Answer: I don t really know Google Search: Photos of Groups of Women Pub Med Search: HIV and Women 22,732

More information

BHIVA Best Practice Management Session

BHIVA Best Practice Management Session BHIVA Best Practice Management Session CNS (The brain) - I keep forgetting things DEMENTIA DIAGNOSIS, CLASSIFICATION AND INVESTIGATIONS Paul Holmes Consultant Neurologist Guy s and St Thomas Hospitals

More information

Selected Issues in HIV Clinical Trials

Selected Issues in HIV Clinical Trials Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic

More information

HIV Antibody Characterization for Reservoir and Eradication Studies. Michael Busch, Sheila Keating, Chris Pilcher, Steve Deeks

HIV Antibody Characterization for Reservoir and Eradication Studies. Michael Busch, Sheila Keating, Chris Pilcher, Steve Deeks HIV Antibody Characterization for Reservoir and Eradication Studies Michael Busch, Sheila Keating, Chris Pilcher, Steve Deeks Blood Systems Research Institute University of California San Francisco, CA

More information

Principles of Antiretroviral Therapy

Principles of Antiretroviral Therapy Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,

More information

0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920

0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920 0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal

More information

Selected Issues in HIV Clinical Trials

Selected Issues in HIV Clinical Trials Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic

More information

Persistent low level viraemia on third line ART

Persistent low level viraemia on third line ART Persistent low level viraemia on third line ART Dr Richard Lessells XXVII International workshop on HIV drug resistance and treatment strategies October 2018 46-year old HIV-positive female HIV diagnosis

More information

This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts

This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts 1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion

More information

Antiretroviral drug treatment of CNS HIV-1 infection

Antiretroviral drug treatment of CNS HIV-1 infection J Antimicrob Chemother 2012; 67: 299 311 doi:10.1093/jac/dkr492 Advance Access publication 8 December 2011 Antiretroviral drug treatment of CNS HIV-1 infection Aylin Yilmaz 1 *, Richard W. Price 2 and

More information

The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines

The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and

More information

Dynamics of Compartmentalized HIV-1 Populations in the Central Nervous System Patrick R. Harrington

Dynamics of Compartmentalized HIV-1 Populations in the Central Nervous System Patrick R. Harrington Dynamics of Compartmentalized HIV-1 Populations in the Central Nervous System Patrick R. Harrington Postdoctoral Fellow Laboratory of Ronald Swanstrom Lineberger Comprehensive Cancer Center University

More information

Industry Data Request

Industry Data Request Industry Data Request Purpose: reported data will be used internally to populate patient forecasting models that are used for business planning. Business planning includes stock requirement forecasts,

More information

ARVs in Development: Where do they fit?

ARVs in Development: Where do they fit? The picture can't be displayed. ARVs in Development: Where do they fit? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker

More information

Perspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation

Perspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation Perspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation Resistance testing has emerged as an important tool for antiretroviral management. Research continues to refine

More information

Towards an HIV Cure. Steven G. Deeks Professor of Medicine University of California, San Francisco

Towards an HIV Cure. Steven G. Deeks Professor of Medicine University of California, San Francisco Towards an HIV Cure Steven G. Deeks Professor of Medicine University of California, San Francisco Why are we now talking about a cure? Emerging recognition that HAART does not fully restore health and/or

More information

Cerebrospinal Fluid (CSF) Neuronal Biomarkers across the Spectrum of HIV Infection: Hierarchy of Injury and Detection

Cerebrospinal Fluid (CSF) Neuronal Biomarkers across the Spectrum of HIV Infection: Hierarchy of Injury and Detection RESEARCH ARTICLE Cerebrospinal Fluid (CSF) Neuronal Biomarkers across the Spectrum of HIV Infection: Hierarchy of Injury and Detection Julia Peterson 1, Magnus Gisslen 2, Henrik Zetterberg 3, Dietmar Fuchs

More information

Dr Jintanat Ananworanich

Dr Jintanat Ananworanich BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions Dr Jintanat Ananworanich US Military HIV Research Program in Bethesda Maryland, USA 9-10 October 2014, Queen Elizabeth II Conference Centre,

More information

Professor Jonathan Weber

Professor Jonathan Weber HIV/AIDS at 30: Back to the Future BHIVA / Wellcome Trust Multidisciplinary Event to mark World AIDS Day 2011 British HIV Association (BHIVA) 2011 HIV/AIDS at 30: Back to the Future BHIVA / Wellcome Trust

More information

Treatment experience in South Africa. Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand

Treatment experience in South Africa. Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand Treatment experience in South Africa Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand Overview South African Prevalence Adherence Combination ddi + d4t Nevirapine Hepatotoxicity

More information

Cases from the Clinic(ians): Case-Based Panel Discussion

Cases from the Clinic(ians): Case-Based Panel Discussion Cases from the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine The University of Alabama at Birmingham EDITED: 03-12-14 Learning Objectives After attending this presentation,

More information

British HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2

British HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2 British HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2 Systematic literature search 2.1 Questions and PICO criteria Data bases: Medline,

More information

Longitudinal Assessment Of Blood Brain Barrier Disruption In Primary Hiv Infection And Effect Of Cart Therapy

Longitudinal Assessment Of Blood Brain Barrier Disruption In Primary Hiv Infection And Effect Of Cart Therapy Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine January 2017 Longitudinal Assessment Of Blood Brain Barrier Disruption

More information

Structured Treatment Interruption in HIV Positive Patients. Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007

Structured Treatment Interruption in HIV Positive Patients. Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007 Structured Treatment Interruption in HIV Positive Patients Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007 Objectives To become re-acquainted with the basics of HAART for HIV infection

More information

TB/HIV Co-Infection. Tuberculosis and HIV

TB/HIV Co-Infection. Tuberculosis and HIV TB Intensive Tyler, Texas June 2-4, 2010 TB/HIV Co-Infection Lisa Y Armitige, MD, PhD June 3, 2010 Tuberculosis and HIV Co-Infection Lisa Y Armitige, MD, PhD Medical Consultant Heartland National TB Center

More information

HIV & Aging: Evolving Clinical Considerations in the New Millennium

HIV & Aging: Evolving Clinical Considerations in the New Millennium HIV & Aging: Evolving Clinical Considerations in the New Millennium Julian Falutz, MD, FRCP (C) Director, HIV Metabolic Clinic Immunodeficiency Treatment Centre Senior Physician Division of Geriatrics

More information

HIV/Sexual Health Clinical Education Session

HIV/Sexual Health Clinical Education Session HIV/Sexual Health Clinical Education Session http://courses.ashm.org.au/hiv/hiv-sexual-health-clinical-education-session/ About These Slide These slides may not be published, posted online, or used in

More information

Antiviral Therapy 2011; 16: (doi: /IMP1851)

Antiviral Therapy 2011; 16: (doi: /IMP1851) Antiviral Therapy 2011; 16:925 929 (doi: 10.3851/IMP1851) Short communication Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure

More information

Case # 1. Case #1 (cont d)

Case # 1. Case #1 (cont d) Antiretroviral Therapy Management: Expert Panel Discussion George Beatty Susa Coffey Steve O Brien December 3, 2011 Moderated by Annie Luetkemeyer Case # 1 38 y.o. man, CD4 =350, VL=340K, new to your clinic

More information

TB Intensive Tyler, Texas December 2-4, Tuberculosis and HIV Co-Infection. Lisa Y. Armitige, MD, PhD. December 4, 2008.

TB Intensive Tyler, Texas December 2-4, Tuberculosis and HIV Co-Infection. Lisa Y. Armitige, MD, PhD. December 4, 2008. TB Intensive Tyler, Texas December 2-4, 2008 Tuberculosis and HIV Co-Infection Lisa Y. Armitige, MD, Ph.D. December 4, 2008 Tuberculosis and HIV Co Infection Lisa Y. Armitige, MD, PhD Assistant Professor

More information

Virological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo

Virological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline

More information

CLAUDINE HENNESSEY & THEUNIS HURTER

CLAUDINE HENNESSEY & THEUNIS HURTER HIV/AIDS/TB CLAUDINE HENNESSEY & THEUNIS HURTER KEY TERMS Do these sound familiar? What strange terms do you hear in the clinics? Any others to add?? HIV AIDS Viral Load & suppression CD4 count Regimen

More information

DATA SHEET. Provided: 500 µl of 5.6 mm Tris HCl, 4.4 mm Tris base, 0.05% sodium azide 0.1 mm EDTA, 5 mg/liter calf thymus DNA.

DATA SHEET. Provided: 500 µl of 5.6 mm Tris HCl, 4.4 mm Tris base, 0.05% sodium azide 0.1 mm EDTA, 5 mg/liter calf thymus DNA. Viral Load DNA >> Standard PCR standard 0 Copies Catalog Number: 1122 Lot Number: 150298 Release Category: A Provided: 500 µl of 5.6 mm Tris HCl, 4.4 mm Tris base, 0.05% sodium azide 0.1 mm EDTA, 5 mg/liter

More information

Introduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School

Introduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Introduction to HIV Drug Resistance Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Objectives 1. Describe the epidemiology of HIV drug resistance in sub-saharan Africa. 2.

More information

Impact of Vorinostat Treatment of Non- Hodgkin s Lymphoma on HIV-1 Latent Reservoir

Impact of Vorinostat Treatment of Non- Hodgkin s Lymphoma on HIV-1 Latent Reservoir Impact of Vorinostat Treatment of Non- Hodgkin s Lymphoma on HIV-1 Latent Reservoir Adam Capoferri, Juan Carlos Ramos, Daniel Xu, Daniel I.S. Rosenbloom, Janet D. Siliciano, Robert F. Siliciano, Ariela

More information

Nuclear Receptors Mediated Induction of P-glycoprotein by Antiretroviral Drugs in Human Brain Microvessel Endothelial Cells

Nuclear Receptors Mediated Induction of P-glycoprotein by Antiretroviral Drugs in Human Brain Microvessel Endothelial Cells Under The Microscope: The Impact of ARTs Nuclear Receptors Mediated Induction of P-glycoprotein by Antiretroviral Drugs in Human Brain Microvessel Endothelial Cells Gary N.Y. Chan, Ph. D. Candidate Supervisor:

More information

0% 0% 0% Parasite. 2. RNA-virus. RNA-virus

0% 0% 0% Parasite. 2. RNA-virus. RNA-virus HIV/AIDS and Treatment Manado, Indonesia 16 november HIV [e] EDUCATION HIV is a 1. DNA-virus 2. RNA-virus 3. Parasite 0% 0% 0% DNA-virus RNA-virus Parasite HIV HIV is a RNA-virus. HIV is an RNA virus which

More information

Dr Anna Herasimtschuk

Dr Anna Herasimtschuk 19 th Annual Conference of the British HIV Association (BHIVA) Dr Anna Herasimtschuk Imperial College London 16-19 April 213, Manchester Central Convention Complex Therapeutic immunisation in conjunction

More information

Didactic Series. Update: 2012 HIV Treatment Guidelines. Daniel Lee, MD August 30, 2012

Didactic Series. Update: 2012 HIV Treatment Guidelines. Daniel Lee, MD August 30, 2012 Didactic Series Update: 2012 HIV Treatment Guidelines Daniel Lee, MD August 30, 2012 ACCREDITATION STATEMENT: University of California, San Diego School of Medicine is accredited by the Accreditation Council

More information

HIV Drugs and the HIV Lifecycle

HIV Drugs and the HIV Lifecycle HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's

More information

Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.

Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H. Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community

More information

Gaps between Policy and Practice in Managing HIV disease in Asia Pacific

Gaps between Policy and Practice in Managing HIV disease in Asia Pacific Gaps between Policy and Practice in Managing HIV disease in Asia Pacific Dr. N. Kumarasamy Chief Medical Officer YRGCARE Medical Centre Voluntary Health Services Chief-Chennai Antiviral Research and Treatment

More information

PROSPECTS FOR HIV CURE IN ADULTS. Nov 11 th 2013 John Frater

PROSPECTS FOR HIV CURE IN ADULTS. Nov 11 th 2013 John Frater PROSPECTS FOR HIV CURE IN ADULTS FIS 2013 Nov 11 th 2013 John Frater April 29 th 2013; Telegraph online THE COMPONENTS OF A CURE. What is cure? Issues to consider: Post treatment control the benefit of

More information

NOTICE TO PHYSICIANS. Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health

NOTICE TO PHYSICIANS. Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health NOTICE TO PHYSICIANS DATE: March 10, 2003 TO: FROM: SUBJECT: HIV/AIDS Health Care Providers Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health

More information

HIV - Therapy Principles

HIV - Therapy Principles HIV - Therapy Principles Manuel Battegay and Christine Katlama Basel, Switzerland and Paris, France Disclosure MB has received honoraria for advisory board participation from Gilead, MSD, Pfizer, ViiV

More information

Susan L. Koletar, MD

Susan L. Koletar, MD HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades

More information

EXPLORING THE IMPACT OF SEX DISCREPANCIES IN HIV TREATMENT AND CURE

EXPLORING THE IMPACT OF SEX DISCREPANCIES IN HIV TREATMENT AND CURE EXPLORING THE IMPACT OF SEX DISCREPANCIES IN HIV TREATMENT AND CURE CECILE DELILLE LAHIRI, M.D, M.SC ASSISTANT PROFESSOR DIVISION OF INFECTIOUS DISEASES MAY 18, 2016 OUTLINE Describe discrepancy between

More information

HIV eradication symposium: will the brain be left behind?

HIV eradication symposium: will the brain be left behind? J. Neurovirol. (2015) 21:322 334 DOI 10.1007/s13365-015-0322-6 EDITORIAL HIV eradication symposium: will the brain be left behind? B. J. Brew & K. Robertson & E. J. Wright & M. Churchill & S. M. Crowe

More information

IAS 2013 Towards an HIV Cure Symposium

IAS 2013 Towards an HIV Cure Symposium In chronically HIV-1-infected patients long-term antiretroviral therapy initiated above 500 CD4/mm 3 achieves better HIV-1 reservoirs' depletion and T-cell count restoration IAS 2013 Towards an HIV Cure

More information

Therapeutic Immunization with Autologous DC Pulsed with Autologous Inactivated HIV-1 Infected Apoptotic Cells

Therapeutic Immunization with Autologous DC Pulsed with Autologous Inactivated HIV-1 Infected Apoptotic Cells Therapeutic Immunization with Autologous DC Pulsed with Autologous Inactivated HIV-1 Infected Apoptotic Cells Sharon A. Riddler, MD, MPH University of Pittsburgh May 2008 Slide 1 HIV and DC Vaccines During

More information

SEXUAL TRANSMISSION. SEXUAL TRANSMISSION under ART: Biological Considerations

SEXUAL TRANSMISSION. SEXUAL TRANSMISSION under ART: Biological Considerations SEXUAL TRANSMISSION under ART: Biological Considerations Dr Steve Taylor, MB ChB, FRCP, PhD Consultant Physician, HIV/GU Medicine, Lead Consultant HIV Services, Directorate of Sexual Medicine and HIV Birmingham

More information

Inclusion/Exclusion Criteria

Inclusion/Exclusion Criteria The Immunomodulatory Effects of Intensification among ART-suppressed Patients with Incomplete CD4 Recovery Peter W. Hunt, Nancy Shulman, Tim Hayes, Viktor Dahl, Ma Somsouk, Nick Funderburg, Alan L. Landay,

More information

Establishment and Targeting of the Viral Reservoir in Rhesus Monkeys

Establishment and Targeting of the Viral Reservoir in Rhesus Monkeys Establishment and Targeting of the Viral Reservoir in Rhesus Monkeys Dan H. Barouch, M.D., Ph.D. Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center Ragon Institute of MGH, MIT,

More information

Diagnosis and Monitoring of HAND

Diagnosis and Monitoring of HAND Diagnosis and Monitoring of HAND Norman C. Moore, MD Professor, Director of Research Department of Psychiatry and Behavioral Sciences Quillen College of Medicine APA 2015 Disclosure: Karl Goodkin, MD,

More information

Antiretroviral Treatment Strategies: Clinical Case Presentation

Antiretroviral Treatment Strategies: Clinical Case Presentation Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.

More information

HIV Associated Neurocognitive Disorders in the era of modern CART

HIV Associated Neurocognitive Disorders in the era of modern CART HIV Associated Neurocognitive Disorders in the era of modern CART Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego Points to be covered HIV associated

More information